GLP-1 Agonist Fails to Improve Coronary Flow Reserve in New Study
Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.
Read More
TZD Effective Third-Line Rx after Failure of Long-term Metformin/GLP-1 RA
This novel study examines the effect of adding another oral agent, rather than insulin, to patients with type 2 diabetes not controlled on metformin plus exenatide.
What Impact of Weight on GLP-1-stimulated Insulin Secretion?
The size of the incretin effect among healthy subjects may vary up to 2-fold, suggesting differences in ß-cell sensitivity to GLP-1. Does BMI play a role in this variability?
Adherence to GLP-1 Therapy Yields Better A1c Outcomes, Higher Costs
Adherent patients were more likely to achieve at least a 1.0% drop in A1c; half achieved the ADA-prescribed goal of <7%. Higher cost was not a surprise.
Poor GLP-1 Response Seen Before Type 2 Diabetes Develops
A Danish study found reduced endogenous levels of glucagon-like peptide-1 in persons with prediabetes. Perhaps the incretin system defect comes first.
Dulaglutide Bests Sitagliptin: Review of AWARD-5
At 52 weeks, dulaglutide resulted in significantly greater reductions in HbA1c, FPG, and weight compared with the DPP-4 inhibitor sitagliptin.
LEADER 2: Prelim Results Show Baseline CT Concentrations High
Early results also found an inverse relationship between serum CT levels and estimated glomerular filtration rate.
3-month HbA1c Predicts Success of GLP-1 RA Therapy
Not all patients with type 2 diabetes respond equally to GLP-1 receptor agonists. Results of a recent study suggest what to look for before you write that next Rx.
GLP-1 Receptor Agonists and Cardiovascular Outcomes: 3 Studies
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
No Risk of Acute Pancreatitis Seen with Incretin-Based Therapies
Results of a population-based case-control study point to a general underlying diabetes effect on pancreatitis risk, rather than a specific drug effect.
Once-Weekly GLP-1 Agonist Added to Oral Agents Lowers A1c
Researchers saw a rapid and durable response to the addition of albiglutide in T2DM patients not reaching glycemic targets on dual oral therapy.
Weight Loss Before Bariatric Surgery in T2DM: GLP-1 Agonist Gets it Done
Pre-surgical weight loss in obese patients with type 2 diabetes reduces perioperative risk. The dual benefits of GLP-1 agonists offer promise to this hard-to-treat population.
GLP-1 Receptor Agonist Approved for Weight Control
Liraglutide 3 mg (Saxenda) is approved for use in adults with BMI >30 or with BMI >27 and one significant obesity-related condition.
GLP-1 Agonist, Basal Insulin Powerful Against T2DM
A recent meta-analysis found that patients treated with a combination of a GLP-1 agonist and basal insulin had a significantly greater A1c reduction than patients on any other treatment regimen.
SGLT-1/SGLT-2 Inhibitor Shows Promise in Patients with T2DM, Renal Impairment
The investigational LX4211 may one day fill a need for these patients who are unable to eliminate a lot of glucose in urine and who respond poorly to selective SGLT2 inhibitors.
SGLT2 Inhibitor Lowers Blood Pressure Across Medication Classes
In patients taking SGLT2 inhibitors who had treated hypertension, a new study found the drop in blood pressure seen with a diuretic similar to declines seen with other classes of antihypertensive medications.
SGLT2 Inhibitor Reduces Visceral Adiposity in T2DM
The mechanism underlying the ability of empagliflozin to reduce measures of visceral adiposity may be a redistribution of fat to less vulnerable body areas.
Cost of Care Lower with SGLT2 Inhibitor vs DPP-4 Inhibitor
Some of the reasons cited for the observed cost efficiencies: better achievement of A1C and composite quality-of-care goals and fewer treatment failures.
Add-On Therapy With DPP-4 Plus SGLT2 Inhibitor Lowered A1c Better Than Either Added Alone
In patients with A1c poorly controlled on metformin, dual add-on therapy with saxagliptin plus dapagliflozin brought more to A1c goals than either drug added alone.
SGLT2 Inhibitor Tested in Type 1 Diabetes
Hypoglycemia was common among study participants but those who received dapagliflozin had reductions in daily average serum glucose levels, glycemic variability, and percent change in total daily insulin dose.
Empagliflozin Lowered BP in Patients with T2DM and Hypertension
The SGLT2 inhibitor in clinical trials was associated with decreases in systolic blood pressure. The current study looked specifically at the drug's effect on blood pressure--with encouraging results.